[go: up one dir, main page]

PL3621960T3 - Tienopirydyny i benzotiofeny użyteczne jako inhibitory irak4 - Google Patents

Tienopirydyny i benzotiofeny użyteczne jako inhibitory irak4

Info

Publication number
PL3621960T3
PL3621960T3 PL18727589T PL18727589T PL3621960T3 PL 3621960 T3 PL3621960 T3 PL 3621960T3 PL 18727589 T PL18727589 T PL 18727589T PL 18727589 T PL18727589 T PL 18727589T PL 3621960 T3 PL3621960 T3 PL 3621960T3
Authority
PL
Poland
Prior art keywords
thyenopyridines
iraq4
benzothiophenes
inhibitors
useful
Prior art date
Application number
PL18727589T
Other languages
English (en)
Inventor
Saleem Ahmad
Ling Li
Lidet A. Negash
John Hynes
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL3621960T3 publication Critical patent/PL3621960T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL18727589T 2017-05-11 2018-05-10 Tienopirydyny i benzotiofeny użyteczne jako inhibitory irak4 PL3621960T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762504956P 2017-05-11 2017-05-11
PCT/US2018/031945 WO2018209012A1 (en) 2017-05-11 2018-05-10 Thienopyridines and benzothiophenes useful as irak4 inhibitors
EP18727589.6A EP3621960B1 (en) 2017-05-11 2018-05-10 Thienopyridines and benzothiophenes useful as irak4 inhibitors

Publications (1)

Publication Number Publication Date
PL3621960T3 true PL3621960T3 (pl) 2021-11-08

Family

ID=62245511

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18727589T PL3621960T3 (pl) 2017-05-11 2018-05-10 Tienopirydyny i benzotiofeny użyteczne jako inhibitory irak4

Country Status (29)

Country Link
US (1) US10829496B2 (pl)
EP (1) EP3621960B1 (pl)
JP (1) JP7154229B2 (pl)
KR (1) KR102604900B1 (pl)
CN (1) CN110612298B (pl)
AR (1) AR111689A1 (pl)
AU (1) AU2018265130B2 (pl)
BR (1) BR112019023290A2 (pl)
CA (1) CA3062602A1 (pl)
CL (1) CL2019003198A1 (pl)
CO (1) CO2019012494A2 (pl)
CY (1) CY1124552T1 (pl)
DK (1) DK3621960T3 (pl)
EA (1) EA039189B1 (pl)
ES (1) ES2889926T3 (pl)
HR (1) HRP20211583T1 (pl)
HU (1) HUE056493T2 (pl)
IL (1) IL270494B (pl)
LT (1) LT3621960T (pl)
MX (1) MX2019012929A (pl)
MY (1) MY200228A (pl)
PE (1) PE20191817A1 (pl)
PL (1) PL3621960T3 (pl)
PT (1) PT3621960T (pl)
RS (1) RS62430B1 (pl)
SI (1) SI3621960T1 (pl)
SM (1) SMT202100568T1 (pl)
TW (1) TW201900640A (pl)
WO (1) WO2018209012A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL295603B2 (en) 2017-09-22 2024-03-01 Kymera Therapeutics Inc Protein degraders and uses thereof
EP3684366A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES OF THE LATEST
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
EP3886904A4 (en) 2018-11-30 2022-07-13 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
KR20220035447A (ko) 2019-07-18 2022-03-22 브리스톨-마이어스 스큅 컴퍼니 IRAK4 억제제로서 유용한 피라졸로[3,4-d]피롤로[1,2-b]피리다지닐 화합물
ES2961950T3 (es) 2019-07-18 2024-03-14 Bristol Myers Squibb Co Compuestos heteroarílicos tricíclicos útiles como inhibidores de IRAK4
EP4004000B1 (en) * 2019-07-23 2025-07-09 Bristol-Myers Squibb Company Thienopyridinyl and thiazolopyridinyl compounds useful as irak4 inhibitors
CN114174279B (zh) 2019-08-06 2024-07-02 百时美施贵宝公司 可用作irak4抑制剂的双环杂环化合物
TW202136251A (zh) 2019-12-17 2021-10-01 美商凱麥拉醫療公司 Irak降解劑及其用途
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021158495A1 (en) 2020-02-03 2021-08-12 Bristol-Myers Squibb Company Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors
CN111285844B (zh) * 2020-02-24 2022-08-12 河南师范大学 具有生物活性的苯并噻吩取代酰胺类化合物及其合成方法和应用
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
AR124547A1 (es) 2020-12-30 2023-04-05 Kymera Therapeutics Inc Degradadores de irak y sus usos
US12171768B2 (en) 2021-02-15 2024-12-24 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
TW202309030A (zh) 2021-05-07 2023-03-01 美商凱麥拉醫療公司 Cdk2降解劑及其用途
JP2024540080A (ja) 2021-10-29 2024-10-31 カイメラ セラピューティクス, インコーポレイテッド Irak4分解剤およびその合成
JP2025504059A (ja) 2022-01-31 2025-02-06 カイメラ セラピューティクス, インコーポレイテッド Irakデグレーダー及びその使用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8627698D0 (en) * 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
ATE432929T1 (de) 2001-06-15 2009-06-15 Vertex Pharma 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
ES2373226T3 (es) 2002-06-28 2012-02-01 Astellas Pharma Inc. Derivado de diaminopirimidincarboxamida.
JP2006516561A (ja) 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての2−アミノピリジン置換ヘテロ環類
WO2005007646A1 (en) 2003-07-10 2005-01-27 Neurogen Corporation Substituted heterocyclic diarylamine analogues
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
US20060281778A1 (en) 2005-03-09 2006-12-14 Schering Corporation Compounds for inhibiting KSP Kinesin activity
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US8003662B2 (en) 2006-01-30 2011-08-23 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
WO2008148889A1 (en) 2007-06-08 2008-12-11 Bayer Cropscience Sa Fungicide heterocyclyl-pyrimidinyl-amino derivatives
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
JP5254693B2 (ja) 2008-07-30 2013-08-07 三菱重工業株式会社 Ni基合金用溶接材料
EP2361902A4 (en) 2008-11-21 2012-04-25 Astellas Pharma Inc 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG
CA2745004C (en) 2008-11-28 2014-07-15 Kowa Company, Ltd. Pyridine-3-carboxyamide derivative
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
EP2440204B1 (en) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
AU2010289353B2 (en) 2009-09-03 2016-12-08 Allergan, Inc. Compounds as tyrosine kinase modulators
JP5770198B2 (ja) 2009-10-30 2015-08-26 ヤンセン ファーマシューティカ エヌ.ベー. オピオイド受容体調節因子としてのフェノキシ置換ピリミジン
CN102971304A (zh) 2010-02-01 2013-03-13 日本化学医药株式会社 Gpr119激动剂
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
RU2013148405A (ru) 2011-04-29 2015-06-10 Айкан Скул Оф Медисин Эт Маунт Синай Ингибиторы киназ
CN104169275B (zh) 2012-01-13 2017-06-09 百时美施贵宝公司 用作激酶抑制剂的三唑取代的吡啶化合物
WO2013106641A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
EP2802576B1 (en) 2012-01-13 2018-06-27 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
TW201422606A (zh) 2012-11-08 2014-06-16 必治妥美雅史谷比公司 可作爲激酶調節劑之經雙環雜環取代之吡啶化合物
EA028526B1 (ru) 2012-11-08 2017-11-30 Бристол-Майерс Сквибб Компани АЛКИЛАМИДЗАМЕЩЕННЫЕ ПИРИДИЛЬНЫЕ СОЕДИНЕНИЯ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ОТВЕТОВ, ОПОСРЕДУЕМЫХ IL-12, IL-23 И/ИЛИ IFNα
CA2890983A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲IL-12、IL-23及/或IFNα反應調節劑之經烷基-醯胺取代之吡啶化合物
BR112016023117B1 (pt) 2014-04-04 2023-02-07 Pfizer Inc Compostos de heteroarila ou arila bicíclicos fundidos
WO2016144849A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Thienopyrazine inhibitors of irak4 activity
EP3268367B8 (en) * 2015-03-12 2022-11-16 Merck Sharp & Dohme LLC Carboxamide inhibitors of irak4 activity
UY36747A (es) 2015-06-24 2016-12-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen
TW201718571A (zh) 2015-06-24 2017-06-01 必治妥美雅史谷比公司 經雜芳基取代之胺基吡啶化合物
KR102029124B1 (ko) 2015-08-27 2019-10-07 화이자 인코포레이티드 Irak4 조정제로서의 비시클릭-융합된 헤테로아릴 또는 아릴 화합물

Also Published As

Publication number Publication date
WO2018209012A1 (en) 2018-11-15
US10829496B2 (en) 2020-11-10
TW201900640A (zh) 2019-01-01
AU2018265130B2 (en) 2022-03-24
SI3621960T1 (sl) 2021-11-30
CO2019012494A2 (es) 2020-01-17
CN110612298B (zh) 2023-05-05
PE20191817A1 (es) 2019-12-27
AR111689A1 (es) 2019-08-07
PT3621960T (pt) 2021-09-16
CY1124552T1 (el) 2022-07-22
JP7154229B2 (ja) 2022-10-17
AU2018265130A1 (en) 2020-01-02
HRP20211583T1 (hr) 2022-01-07
LT3621960T (lt) 2021-10-11
KR20200004871A (ko) 2020-01-14
MY200228A (en) 2023-12-15
EA201992674A1 (ru) 2020-04-06
KR102604900B1 (ko) 2023-11-21
JP2020519596A (ja) 2020-07-02
CA3062602A1 (en) 2018-11-15
BR112019023290A2 (pt) 2020-06-16
HUE056493T2 (hu) 2022-02-28
ES2889926T3 (es) 2022-01-14
IL270494B (en) 2022-04-01
MX2019012929A (es) 2020-01-14
DK3621960T3 (da) 2021-09-27
RS62430B1 (sr) 2021-11-30
EA039189B1 (ru) 2021-12-15
EP3621960A1 (en) 2020-03-18
CL2019003198A1 (es) 2020-03-20
CN110612298A (zh) 2019-12-24
SMT202100568T1 (it) 2021-11-12
EP3621960B1 (en) 2021-08-04
US20200062777A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
PL3621960T3 (pl) Tienopirydyny i benzotiofeny użyteczne jako inhibitory irak4
IL283639A (en) Kif18a inhibitors
IL269196A (en) Novel inhibitors
MA54550A (fr) Inhibiteurs de kif18a
EP3898616C0 (en) HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS
EP3898592C0 (en) HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS
PL3468966T3 (pl) Inhibitory interakcji menina-mll
DK3612525T3 (da) Pd-1-/pd-l1-inhibitorer
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
MA52812A (fr) Inhibiteurs de sarm1
EP3626699A4 (en) SSAO INHIBITOR
PL3154989T3 (pl) Inhibitory beta-laktamaz
DK3536685T3 (da) Bicyklisk-fusionerede heteroaryl- eller arylforbindelser og anvendelse deraf som irak4 inhibitorer
PL3500564T3 (pl) Inhibitory acylotransferazy diacyloglicerolu 2
ES2904557T8 (es) Agentes inhibidores de irak4
DK3672976T3 (da) Bcl-2-hæmmere
DK3442972T3 (da) Bromdomænehæmmere
EP3347008A4 (en) BETA-Lactamase INHIBITORS
MA52809A (fr) Inhibiteurs de sarm1
MA52813A (fr) Inhibiteurs de sarm1
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
IL255764A (en) Autotaxin inhibitors and uses thereof
DK3538528T3 (da) Pyrrolamider som alpha v-integrinhæmmere
EP3883573A4 (en) DYRK1A MACROCYCLIC INHIBITORS